TENOFOVIR ALAFENAMIDE HEMIFUMARATE

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of application Ser. No. 13/586,358 filed Aug. 15, 2012, which in turn claims the benefit of priority from U.S. Provisional Patent Application No. 61/524,224, filed Aug. 16, 2011, the content of each of which is hereby incorporated by reference herein in its entirety.

BACKGROUND OF THE INVENTION

Description of Related Art

U.S. Pat. Nos. 7,390,791 and 7,803,788 (the content of each of which is incorporated by reference herein in its entirety) describe certain prodrugs of phosphonate nucleotide analogs that are useful in therapy. One such prodrug is 9-[(R)-2-[[(S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino]phenoxyphosphinyl]methoxy]propyl]adenine. This compound is also known by the Chemical Abstract name L-alanine, N—[(S)-[[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl] phenoxyphosphinyl]-, 1-methylethyl ester. U.S. Pat. Nos. 7,390,791 and 7,803,788 also disclose a monofumarate form of this compound and its preparation method (see, e.g., Example 4).

SUMMARY OF THE INVENTION

Described is a hemifumarate form of 9-[(R)-2-[[(S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino]phenoxyphosphinyl] methoxy]propyl]adenine. The name for 9-[(R)-2-[[(S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino]phenoxyphosphinyl] methoxy]propyl]adenine is tenofovir alafenamide. The hemifumarate form of tenofovir alafenamide is also referred to herein as tenofovir alafenamide hemifumarate.

In one embodiment of the invention is provided tenofovir alafenamide hemifumarate.

In another embodiment is provided tenofovir alafenamide hemifumarate, wherein the ratio of fumaric acid to tenofovir alafenamide is 0.5±0.1, or 0.5±0.05, or 0.5±0.01, or about 0.5.

In one embodiment is provided tenofovir alafenamide hemifumarate in a solid form.

In one embodiment is provided tenofovir alafenamide hemifumarate that has an X-ray powder diffraction (XRPD) pattern having 2theta values of 6.9±0.2° and 8.6±0.2°. In another embodiment is provided tenofovir alafenamide hemifumarate wherein the XRPD pattern comprises 2theta values of 6.9±0.2°, 8.6±0.2°, 11.0±0.2°, 15.9±0.2°, and 20.2±0.2°.

In one embodiment is provided tenofovir alafenamide hemifumarate that has a differential scanning calorimetry (DSC) onset endotherm of 131±2° C., or 131±1° C.

In one embodiment is provided a pharmaceutical composition comprising tenofovir alafenamide hemifumarate and a pharmaceutically acceptable excipient. In another embodiment is provided the pharmaceutical composition, further comprising an additional therapeutic agent. In a further embodiment, the additional therapeutic agent is selected from the group consisting of human immunodeficiency virus (HIV) protease inhibiting compounds, HIV nonnucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, and CCR5 inhibitors.

In one embodiment is provided a method for treating a human immunodeficiency virus (HIV) infection comprising administering to a subject in need thereof a therapeutically effective amount of tenofovir alafenamide hemifumarate. In another embodiment is provided a method for treating an HIV infection comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising tenofovir alafenamide hemifumarate. In a further embodiment, the method comprises administering to the subject one or more additional therapeutic agents selected from the group consisting of HIV protease inhibiting compounds, HIV nonnucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, and CCR5 inhibitors.

In one embodiment is provided a method for treating a hepatitis B virus (HBV) infection comprising administering to a subject in need thereof a therapeutically effective amount of tenofovir alafenamide hemifumarate. In another embodiment is provided a method for treating an HBV infection comprising administering to a subject in need thereof a therapeutically effective amount of the pharmaceutical composition comprising tenofovir alafenamide hemifumarate.

In one embodiment is provided a method for preparing a pharmaceutical composition comprising combining tenofovir alafenamide hemifumarate and a pharmaceutically acceptable excipient to provide the pharmaceutical composition.

In one embodiment is provided a method for preparing tenofovir alafenamide hemifumarate comprising subjecting a solution comprising a suitable solvent; fumaric acid; tenofovir alafenamide; and, optionally, one or more seeds of tenofovir alafenamide hemifumarate to conditions that provide for the crystallization of the fumaric acid and the tenofovir alafenamide. In one embodiment, the solvent comprises acetonitrile. In another embodiment, the solution is subjected to a temperature in the range of from about 0° C. to about 75° C.

In one embodiment is provided tenofovir alafenamide hemifumarate for use in medical therapy.

In one embodiment is provided the use of tenofovir alafenamide hemifumarate for the prophylactic or therapeutic treatment of an HIV infection. In another embodiment is provided the use of tenofovir alafenamide hemifumarate to treat an HIV infection. In a further embodiment is provided the use of tenofovir alafenamide hemifumarate for the preparation or manufacture of a medicament for the treatment of an HIV infection. In another further embodiment is provided tenofovir alafenamide hemifumarate for use in treating an HIV infection.

In one embodiment is provided the use of tenofovir alafenamide hemifumarate for the prophylactic or therapeutic treatment of an HBV infection. In another embodiment is provided the use of tenofovir alafenamide hemifumarate to treat an HBV infection. In a further embodiment is provided the use of tenofovir alafenamide hemifumarate for the preparation or manufacture of a medicament for the treatment of an HBV infection. In another further embodiment is provided tenofovir alafenamide hemifumarate for use in treating an HBV infection.

In some embodiments of the invention, the methods of treating and the like comprise administration of multiple daily doses. In other embodiments, the methods of treating and the like comprise administration of a single daily dose.

In one embodiment of the invention is provided a composition consisting essentially of tenofovir alafenamide hemifumarate.